Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Crenigacestat by Eli Lilly and Co for Refractory Multiple Myeloma: Likelihood of Approval
Crenigacestat is under clinical development by Eli Lilly and Co and currently in Phase II for Refractory Multiple Myeloma. According...
Crenigacestat by Eli Lilly and Co for Relapsed Multiple Myeloma: Likelihood of Approval
Crenigacestat is under clinical development by Eli Lilly and Co and currently in Phase II for Relapsed Multiple Myeloma. According...
Crenigacestat by Eli Lilly and Co for Natural Killer Cell Lymphomas: Likelihood of Approval
Crenigacestat is under clinical development by Eli Lilly and Co and currently in Phase I for Natural Killer Cell Lymphomas....